Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

BARCELONA, Spain—New guidelines for the diagnosis and treatment of pulmonary hypertension (PH), released at the recent European Society of Cardiology (ESC) Congress 2022, include a new hemodynamic ...

Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...

New European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for diagnosis and treatment of pulmonary hypertension have lowered the cutoff for defining pulmonary hypertension ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

Please provide your email address to receive an email when new articles are posted on . A systemic sclerosis-related pulmonary hypertension diagnosis in the last 10 years vs. 10 years prior was linked ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

A 40-year-old woman who was once accustomed to frequent travel suddenly found herself struggling to breathe after just a few ...